|
|
|
Market Research Report
World Smoking-Cessation Drug Market 2010-2025
| Published by |
Visiongain |
| Published |
January, 2010 |
Product code |
114699 |
| Content info |
123 pages |
| Price |
|
|
World Smoking-Cessation Drug Market 2010-2025 published by Visiongain in January, 2010. This report consists of 123 pages and the price starts from US $ 2331.
Abstract
Smoking is a leading cause of preventable death worldwide. In 2009, total
sales of smoking-cessation products surpassed $1.6bn (Rx products). The
effects of smoking constitute a major burden on public healthcare systems, as
well as lowering quality of life for many people. Currently-marketed
smoking-cessation products arguably lack the desired levels of efficacy in
practice, with the reputation of some suffering through noted side-effects. As
a result, there are significant commercial opportunities for more-efficacious
and better-tolerated smoking-cessation agents, especially in prescription form.
Our new report - World Smoking-Cessation Drug Market 2010-2025 - forecasts how
the anti-smoking drug market will develop over the next 15 years. We predict
that the launch of new smoking-cessation aids early this decade will answer
some unmet needs currently limiting that pharma market segment. Besides
extensive coverage of currently-marketed drugs, this report examines the most
exciting products currently in development. We also include external opinions
on the sector, gained thorough original unique surveys.
Our report analyses current leading markets in North America, Europe and Asia
in detail. A major contribution to the market during the next 15 years will
come from emerging economies, led by India and China. Almost half of the
world' s smokers live in those countries, with almost a third in China alone,
reports suggest. At present, those national markets yield relatively low
smoking-cessation revenues. However, visiongain predicts that the emerging
economies have a large potential for sales growth of smoking-cessation
products. This report reveals how their sales revenues and market shares will
expand during the forecast period.
The majority of smokers worldwide do not have full access to smoking-cessation
therapies at present. The high economic and social costs associated with
tobacco use are driving anti-smoking legislation and encouraging governmental
spending on tobacco-dependency treatments. From 2010 to 2025, the
implementation and expansion of tobacco-control policies - especially public
smoking bans - will continue. Combined, those policies will help to increase
the use of smoking-cessation products, agents still with a long way to go in
their technological and commercial development, our report shows.
Comprehensive analysis of the smoking-cessation pharmaceutical market
World Smoking-Cessation Drug Market 2010-2025 critically examines that sector
through a comprehensive review of primary and secondary information sources.
Our new report provides detailed sales forecasts, market share analyses,
discussions of pipeline developments and analyses of commercial drivers and
restraints. There are over 50 tables and figures included, as well as two
interviews with relevant experts. The result is a comprehensive market- and
industry-centred study, with detailed analyses and informed opinion to benefit
your work.
Highlights of the report include:
- Sales forecasts for the smoking-cessation drug market, leading therapy
types and top products at global level
- Detailed examination of the smoking-cessation markets in the US, Canada,
the UK, France, Germany, Sweden, Denmark, Japan, China and India, with sales
forecasts
- Examination of strengths, weakness, opportunities and threats (SWOT
factors) facing the industry and market
- Analysis of the R&D pipeline for smoking-cessation products.
Why you should buy World Smoking-Cessation Drug Market 2010-2025
This report gives you the following benefits in particular:
- You will receive a comprehensive analysis of the prospects for
smoking-cessation drugs from 2010 to 2025, including predicted revenues,
growth rates and other key metrics
- You will find out where the market is heading - both technologically and
commercially - from the present onwards, both for the overall world market and
for leading national markets
- You will discover prospects for Chantix/Champix, in light of recent
concerns
- You will identify key pipeline developments and up-and-coming products
- You will discover the drivers, restraints, competition and opportunities
influencing the smoking-cessation market, including those for nicotine
replacement therapies, Pfizer' s Chantix/Champix and bupropion drugs
- You will receive expert views from our original unique interviews -
unavailable anywhere else
Our research shows that new smoking-cessation drugs should achieve commercial
success if they are clearly tolerable and more effective in practice than
existing products, easily accessible, backed by innovative marketing campaigns
and delivered in combination with behavioural support programmes.
Smoking-cessation drugs with those characteristics would have good overall
prospects with regulators and healthcare providers.
Table of Contents
1. Executive Summary
2. Introduction to Smoking Cessation
- 2.1 Tobacco
- 2.1.1 Types of Tobacco Consumption
- 2.1.2 Tobacco Addiction is a Major Global Health Problem
- 2.2 Nicotine Addiction
- 2.3 Smoking Cessation
- 2.3.1 Why is it Difficult to Stop Smoking?
- 2.3.2 Methods for Smoking Cessation
3. Pharmacological Smoking-Cessation Products
- 3.1 Nicotine Replacement Therapy (NRT)
- 3.1.1 Nicorette NRT (Johnson & Johnson/Takeda)
- 3.1.2 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK)
- 3.1.3 Novartis NRT Brands
- 3.1.4 Other NRT Manufacturers
- 3.2 Chantix/Champix (varenicline, Pfizer)
- 3.3 Bupropion
- 3.3.1 Zyban (GSK/Biovail)
- 3.3.2 Generic Bupropion Drugs
- 3.4 Off-Label Drug Prescribing for Smoking Cessation
4. The World Smoking-Cessation Market
- 4.1 The World Smoking-Cessation Market Value, 2008-2009
- 4.1.1 Smoking-Cessation Market Value
- 4.1.2 Leading Smoking-Cessation Product Types
- 4.1.3 Leading Smoking-Cessation Brands
- 4.1.4 Leading Smoking-Cessation Manufacturers
- 4.2 The World Smoking-Cessation Market Forecast, 2010-2025
- 4.2.1 Growth in the Smoking-Cessation Market, 2010-2025
- 4.2.2 Emerging Products and Sales Forecast of the Smoking-Cessation
Market, 2010-2025
- 4.2.3 Smoking-Cessation Market from 2010-2020
- 4.2.4 Market Acceleration from 2020 to 2025
- 4.2.5 Smoking-Cessation Product Type Sales Forecast, 2010-2025
5. Individual Market Forecasts for Leading Drugs, 2010-2025
- 5.1 Nicotine Replacement Therapies Sales Forecast, 2010-2025
- 5.1.1 Individual NRT Sales Forecast, 2010-2025
- 5.1.2 Upper Level NRT Sales Forecast, 2010-2025
- 5.1.3 Lower Level NRT Sales Forecast, 2010-2025
- 5.2 Chantix/Champix Sales Forecast, 2010-2025
- 5.3 Bupropion Smoking-Cessation Drugs Sales Forecast, 2010-2025
6. Geographical Breakdown of the Smoking-Cessation Market, 2010-2025
- 6.1 The Leading Smoking-Cessation Markets
- 6.2 Leading Smoking-Cessation Country Markets and Sales Forecast, 2010-2025
- 6.3 The US Smoking-Cessation Market
- 6.3.1 Smoking Prevalence Declining in US
- 6.3.2 Availability and Reimbursement of Smoking-Cessation Aids in the US
- 6.3.3 US Smoking-Cessation Market Revenue, 2008-2009
- 6.3.4 Is there Scope for US Smoking-Cessation Market Expansion?
- 6.3.5 US Smoking-Cessation Market Forecast, 2010-2025
- 6.4 The UK Smoking-Cessation Market
- 6.4.1 Tobacco Use in the UK
- 6.4.2 The UK Pioneers Smoking-Cessation Reimbursement and OTC Retailing
of NRT Products
- 6.4.3 The UK is Europe' s Largest Smoking-Cessation Market
- 6.4.4 UK Government Anti-Smoking Legislation Lifts Market
- 6.4.5 UK Smoking-Cessation Market Forecast, 2010-2025
- 6.5 The Canadian Smoking-Cessation Market
- 6.5.1 Current Smoking Prevalence in Canada
- 6.5.2 Availability and Reimbursement of Smoking-Cessation Products in
Canada
- 6.5.3 Factors Affecting the Canadian Smoking-Cessation Market
- 6.5.4 Canadian Smoking-Cessation Market Forecast, 2010-2025
- 6.6 The Japanese Smoking-Cessation Market
- 6.6.1 Japan has a Relatively Undeveloped Smoking-Cessation Market
- 6.6.2 The Japanese Smoking-Cessation Market, 2008-2010
- 6.6.3 Japanese Smoking-Cessation Market Forecast, 2010-2025
- 6.7 The French Smoking-Cessation Market
- 6.7.1 French Smoking Prevalence
- 6.7.2 The French Smoking-Cessation Market, 2008-2009
- 6.7.3 French Government' s Provision of Smoking-Cessation Aids is Better
than that in Many Other European Countries
- 6.7.4 French Smoking-Cessation Market Forecast, 2010-2025
- 6.8 The Swedish Smoking-Cessation Market
- 6.8.1 Snus in Sweden Increasing in Prevalence
- 6.8.2 The Swedish Smoking-Cessation Market in 2008-2009
- 6.8.3 Swedish Smoking-Cessation Market Forecast, 2010-2025
- 6.9 The Danish Smoking-Cessation Market
- 6.9.1 Smoking Prevalence Still High in Denmark
- 6.9.2 Danish Smoking-Cessation Market Forecast, 2010-2025
- 6.10 The German Smoking-Cessation Market
- 6.10.1 The German Smoking-Cessation Market, 2007-2008
- 6.10.2 Factors Holding Back the German Smoking-Cessation Market
- 6.10.3 German Smoking-Cessation Market Forecast, 2010-2025
7. Emerging Countries in the Smoking-Cessation Market
- 7.1 Greatest Market Growth Predicted in India and China
- 7.2 The Indian Smoking-Cessation Market
- 7.2.1 Tobacco in India is Both Smoked and Chewed
- 7.2.2 The Indian Smoking-Cessation Market, 2008-2009
- 7.2.3 Indian Smoking-Cessation Market Still in its Infancy
- 7.2.4 Prospects for Growth of the Indian Smoking-Cessation Market
- 7.2.5 Indian Smoking-Cessation Market Forecast, 2010-2025
- 7.3 The Chinese Smoking-Cessation Market
- 7.3.1 More than 5 Billion Cigarettes are Smoked in China Every Day
- 7.3.2 The Chinese Smoking-Cessation Market, 2008-2009
- 7.3.3 The Chinese Smoking-Cessation Market is Currently Undeveloped
- 7.3.4 Smoking-Cessation Market Prospects in China and Hong Kong
- 7.3.5 Chinese Smoking-Cessation Market Forecast, 2010-2025
8. Issues Affecting the Smoking-Cessation Market, 2010-2025
- 8.1 SWOT Analysis of the Global Smoking-Cessation Market
- 8.2 Strengths of the Smoking-Cessation Sector
- 8.2.1 Innovation in Smoking-Cessation Therapies
- 8.2.2 Innovative Marketing Techniques
- 8.2.3 Support Plans and Web 2.0 Technology in Combination with
Pharmacotherapy
- 8.2.4 OTC-Switching
- 8.3 Weaknesses of the Smoking-Cessation Sector
- 8.3.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from
Smoking
- 8.3.2 Currently-Marketed Smoking-Cessation Therapies - Relapse Rate
- 8.4 Opportunities for the Smoking-Cessation Market
- 8.4.1 Smoking is Prevalent Worldwide and Slowly Increasing
- 8.4.2 Countries with Untapped Smoking-Cessation Market Potential
- 8.4.3 Growth of Emerging-Economy Smoking-Cessation Markets
- 8.4.4 Health Effects of Tobacco
- 8.4.5 Economic Impact of Tobacco Use
- 8.4.6 Framework Convention on Tobacco Control (FCTC)
- 8.4.7 Government-Sponsored Smoking-Cessation Programmes
- 8.4.8 Increasing Tobacco Taxes
- 8.4.9 Smoking Bans
- 8.4.10 Warning Information on Tobacco Products
- 8.4.11 Bans on Tobacco Advertising, Promotion and Sponsorship
- 8.5 Threats to the Smoking-Cessation Industry
- 8.5.1 Concern over Side-Effects of Smoking-Cessation Drugs
- 8.5.1.1 Champix/Chantix
- 8.5.1.2 Side-Effect Concerns for NRT and Bupropion
- 8.5.1.3 The Result of Side-Effect Concerns
- 8.5.2 Reimbursement for Smoking-Cessation Therapies
- 8.5.3 Traditional Smokeless Tobacco
- 8.5.3.1 Snus and Gutkha
- 8.5.3.2 Possible Impact of Greater Smokeless Tobacco Use
- 8.5.4 The E-Cigarette
- 8.5.4.1 The E-Cigarette Market
- 8.5.4.2 Will E-Cigarettes Revolutionise Tobacco Use and Pose a Threat
to the Smoking-Cessation Market?
- 8.5.4.3 E-Cigarettes and Smoking-Cessation Therapies
9. Expert Interviews
- 9.1 Opinion on the Smoking-Cessation Sector from Dr Scott McIntosh,
Director of the Greater Rochester Tobacco Research Center, USA, and Associate
Director of the Smoking Research Program
- 9.1.1 Unmet Needs of the Smoking-Cessation Market
- 9.1.2 The Greatest Pharmacological Obstacles within the
Smoking-Cessation Market
- 9.1.3 Drivers & Restraints of the Smoking-Cessation Market
- 9.1.4 Drugs and Smokeless Cigarettes
- 9.1.5 Are Vaccines More Effective than NRTs?
- 9.2 Opinion on Nicotine Vaccines from Dr Raafat Fahim, President and Chief
Executive Officer, Nabi Biopharmaceuticals
- 9.2.1 Vaccines in the Pipeline for Nicotine Addiction
- 9.2.2 NicVAX Nicotine Vaccine
- 9.2.3 Other Nicotine Vaccines
10. The Smoking-Cessation Pipeline
- 10.1 Novel Vaccines Will Target Nicotine Addiction
- 10.1.1 NicVAX (Nabi Biopharmaceuticals)
- 10.1.2 TA-NIC (Celtic Pharma)
- 10.1.3 Niccine (Independent Pharmaceutica)
- 10.2 Monoamine Oxidase Inhibitors
- 10.2.1 EVT 302 (Evotec)
- 10.2.2 Selegiline (National Institute on Drug Abuse [NIDA])
- 10.3 Glycine Antagonists
- 10.4 Opiate Antagonists and Agonists
- 10.5 Dopamine D3 Antagonists
- 10.6 Nicotinic Ligands
- 10.7 Dopamine Uptake Inhibitors
- 10.8 Cannabinoid Receptor 1 Antagonists
11. Conclusions
- 11.1 Smoking is One of the Gravest Threats to Health Worldwide
- 11.2 Smoking Cessation
- 11.3 The Smoking-Cessation Market in 2010
- 11.4 World Smoking-Cessation Market: Prospects from 2010 to 2025
- 11.5 Leading and Emerging Smoking-Cessation Markets
- 11.6 Concluding Thoughts on the Market
List of Tables
- Table 3.1 Nicotine Replacement Therapy Types, 2009
- Table 3.2 Nicorette NRT Brands (Johnson & Johnson/Takeda), 2009
- Table 3.3 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK), 2009
- Table 3.4 Novartis NRT Brands, 2009
- Table 3.5 Other NRT Brands, 2009
- Table 3.6 Key Drugs Prescribed Off-Label for Smoking Cessation, 2009
- Table 4.1 World Smoking-Cessation Market: Sales, 2008-2009
- Table 4.2 Leading Smoking-Cessation Product Types: Sales and Market
Shares, 2008-2009
- Table 4.3 Leading Smoking-Cessation Brands: Sales and Market Shares, 2009
- Table 4.4 Leading Manufacturers of Smoking-Cessation Products: Sales and
Market Shares, 2009
- Table 4.5 World Smoking-Cessation Market: Sales Forecast, 2010-2016
- Table 4.6 World Smoking-Cessation Market: Sales Forecast, 2017-2025
- Table 4.7 Smoking-Cessation Product Type: Sales Forecasts, 2010-2016
- Table 4.8 Smoking-Cessation Product Type: Sales Forecasts, 2017-2025
- Table 5.1 Individual NRT Sales: Forecasts with Total Market, 2010-2016
- Table 5.2 Individual NRT Sales: Forecasts with Total Market, 2017-2025
- Table 6.1 Leading Smoking-Cessation Country Markets: Sales, 2009
- Table 6.2 Smoking-Cessation Country Markets: Sales Forecasts, 2010-2016
- Table 6.3 Smoking-Cessation Country Markets: Sales Forecasts, 2017-2025
- Table 8.1 SWOT Analysis of the World Smoking-Cessation Market, 2010-2025
- Table 10.1 Key Smoking-Cessation Pipeline Products, 2009
- Table 11.1 Smoking-Cessation Country Markets: Sales Forecasts, Market
Shares and CAGRs, 2009-2025
List of Figures
- Figure 4.1 Leading Smoking-Cessation Product Types: Market Shares, 2009
- Figure 4.2 Leading Smoking-Cessation Product Types: Market Shares, 2009
- Figure 4.3 Leading Smoking-Cessation Brands: Market Shares, 2009
- Figure 4.4 Leading Manufacturers of Smoking-Cessation Products: Market
Shares, 2009
- Figure 4.5 World Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 4.6 Product Type: Sales Forecast, 2010-2025
- Figure 4.7 Product Type: Sales and Market Shares, 2008, 2010, 2015, 2025
- Figure 5.1 NRT Market Sales: Forecast, 2010-2025
- Figure 5.2 Upper Level NRT Individual Sales: Forecasts, 2010-2025
- Figure 5.3 Lower Level NRT Individual Sales: Forecasts, 2010-2025
- Figure 5.4 Individual NRT Market Shares, 2010
- Figure 5.5 Individual NRT Market Shares, 2015
- Figure 5.6 Individual NRT Market Shares, 2025
- Figure 5.7 Chantix/Champix Sales Forecast, 2010-2025
- Figure 5.8 Bupropion Sales Forecast, 2010-2025
- Figure 6.1 Smoking-Cessation Market Shares by Country, 2009
- Figure 6.2 Smoking-Cessation Market Shares by Country, 2010
- Figure 6.3 Smoking-Cessation Market Shares by Country, 2015
- Figure 6.4 Smoking-Cessation Market Shares by Country, 2025
- Figure 6.5 US Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 6.6 UK Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 6.7 Canadian Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 6.8 Japanese Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 6.9 French Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 6.10 Swedish Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 6.11 Danish Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 6.12 German Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 7.1 World Smoking-Cessation Markets: CAGRs, 2009-2025
- Figure 7.2 Indian Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 7.3 Chinese Smoking-Cessation Market: Sales Forecast, 2010-2025
- Figure 11.1 World Smoking-Cessation Market: Sales Forecast, 2010-2025
Companies Listed
- Action on Smoking on Health (ASH) [UK]
- American Heart Association (AHA) [US]
- American Lung Association (ALA) [US]
- Biotie Therapies [Finland]
- Biovail
- Boehringer Ingelheim
- Ceejay Healthcare
- Celtic Pharma
- Centers for Disease Control and Prevention (CDC) [US]
- Cytos Biotechnology
- European Medicines Agency (EMEA)
- Evotec
- Food and Drug Administration (FDA) [US]
- Georgetown University School of Medicine [US]
- GlaxoSmithKline (GSK)
- Greater Rochester Tobacco Research Center
- Independent Pharmaceutica
- Johnson & Johnson
- Karolinska Institutet [Sweden]
- Lundbeck
- Mayo Clinic [US]
- Medical College of Wisconsin Research Foundation [US]
- Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
- Ministry of Health, Labour and Welfare (MHLW) [Japan]
- Mylan
- Nabi Biopharmaceuticals
- National Cancer Institute (NCI) [US]
- National Health Service (NHS) [UK]
- National Institute for Health and Clinical Excellence (NICE) [UK]
- National Institute of Drug Abuse (NIDA) [US]
- National Institutes of Health (NIH) [US]
- Novartis
- Perrigo
- Pfizer
- Pierre Fabre
- Ruyan
- Sanofi-Aventis
- Sigma
- The Smoking Research Program [US]
- Somaxon
- Sopharma
- Taisho
- Takeda
- Targacept
- Teva
- University of California [US]
- Watson
- World Health Organization (WHO)
- Zenara
|
 |
